Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye800CW in breast cancer surgery
NCT02583568Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2015
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab-IRDye800CW in breast cancer, sponsored by University Medical Center Groningen. Started Oct 2015; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02583568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583568.